EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta‐Analysis

Magnus A B Axelsson iD, Naldy Parodi López iD, Eva Wikström Jonsson iD, Susanna M Wallerstedt iD

Basic & Clinical Pharmacology & Toxicology · 2025-08 · 137 (2)

DOI: 10.1111/bcpt.70087 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 21.07.2025. Verfasst von Magnus A B Axelsson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden. Hauptthemen laut MEDLINE: Clopidogrel, Proton Pump Inhibitors, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish state under the ALF agreement between the Swedish government and the county councils, Swedish Research Council, Vetenskapsrådet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Classifications of drug interaction alerts regarding clopidogrel and a proton pump inhibitor (PPI) differ between knowledge resources. In this systematic review, Medline, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) applying PICO criteria: P = patients on clopidogrel; I = intervention: PPI (subgroup: [es]omeprazole); C = comparison: no PPI (C1) or a PPI other than (es)omeprazole (C2); O = outcomes, main: a composite of cardiovascular events (efficacy); also: overt gastrointestinal bleeding (safety). Fourteen RCTs fulfilled the PICO criteria, five without high risk of bias and with at least one clinical event per study arm. Regarding efficacy with or without a PPI, the pooled risk ratio (RR) and risk difference (RD) were 1.08 (95% confidence interval (CI) 0.78; 1.50) and 0.2 percentage points (95% CI −0.9; 1.2), respectively (four RCTs; 4341 patients [96% also used aspirin, 98% receiving I used (es)omeprazole]; moderate certainty evidence). Regarding safety, the RR and RD were 0.13 (95% CI 0.03; 0.59) and −0.7 percentage points (95% CI −1.1; −0.3), respectively (one RCT; 3761 patients; moderate certainty evidence). The available evidence did not allow conclusions regarding omeprazole versus pantoprazole. In conclusion, concurrent use of a PPI probably does not largely affect clopidogrel efficacy, but probably reduces the risk of overt gastrointestinal bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelProton Pump InhibitorsPlatelet Aggregation InhibitorsHumansDrug InteractionsGastrointestinal HemorrhageRandomized Controlled Trials as TopicOmeprazoleDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

(es)omeprazoleclopidogreldrug interactionefficacyproton pump inhibitor

Substanzen

ClopidogrelProton Pump InhibitorsPlatelet Aggregation InhibitorsOmeprazole

Autor:innen und Institutionen

  • Laboratory of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
  • Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Clinical Pharmacology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Laboratory Medicine/Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden.
  • Department of Clinical Pharmacology, Medical Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
  • Center for Health Technology Assessment, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.

ORCID-Profile: Magnus A B Axelsson, Naldy Parodi López, Eva Wikström Jonsson, Susanna M Wallerstedt

Förderung

  • Swedish state under the ALF agreement between the Swedish government and the county councils
  • Swedish Research Council
  • Vetenskapsrådet

Zitieren

APA

Axelsson, M. A. B., Parodi López, N., Wikström Jonsson, E., & Wallerstedt, S. M. (2025). Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta‐Analysis. Basic & Clinical Pharmacology & Toxicology, 137(2). https://doi.org/10.1111/bcpt.70087

Vancouver

Axelsson MAB, Parodi López N, Wikström Jonsson E, Wallerstedt SM. Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta‐Analysis. Basic & Clinical Pharmacology & Toxicology. 2025;137(2). doi:10.1111/bcpt.70087

BibTeX
@article{Axelsson2025,
  author = {Axelsson, Magnus A B and Parodi López, Naldy and Wikström Jonsson, Eva and Wallerstedt, Susanna M},
  title = {Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta‐Analysis},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  volume = {137},
  number = {2},
  doi = {10.1111/bcpt.70087}
}
Kostenlos starten →